Abstract:

Several antimuscarinic agents are available for the treatment of overactive bladder but there are few head-to-head studies to guide physicians in choosing one over another. Here we propose ways in which logical adjustments can be made to account for differences in disease severity and placebo effects when considering continence data to allow estimation of relative effectiveness across studies.

Keywords: ANTIMUSCARINIC THERAPY; CROSS-STUDY COMPARISONS; INCONTINENCE; OVERACTIVE BLADDER; PLACEBO EFFECT

Document Type: Miscellaneous

DOI: 10.1185/0300799005X48393

Affiliations: 1: Department of Urology, New York Presbyterian Hospital, New York, USA 2: Department of Urology, University of Pennsylvania, Philadelphia, PA, USA